The Institute is made up of dedicated drug discovery teams led by a Chief Scientific Officer and Lead Academic Scientists.
Chief Scientific Officer (CSO)
Our Chief Scientific Officer (CSO) leads the UCL Drug Discovery Institute and drives scientific progress. Please get in touch if you’d like to discuss potential collaborations.
Paul obtained a first-class honours degree from the University of Leeds, followed by a PhD in Biochemistry at the University of London. He moved to the Salk Institute for Biological Studies in San Diego for his postdoc, before joining the Neuroscience Research Centre, Merck Research Laboratories where he moved from lab scientist to Head of Molecular and Cellular Neurosciences.
Paul joined Pfizer in 2006 and went on to help establish the new Pfizer Regenerative Medicine research unit in Cambridge UK, leading the small molecule and cell therapy programs. In 2011 the regenerative medicine activities were incorporated into a new Pfizer research unit, “Neusentis”, where he was Head of Molecular and Cellular Biology. In October 2015, Paul moved to UCL Institute of Neurology to become the Chief Scientific Officer for the Alzheimer’s Research UK UCL Drug Discovery Institute. In 2017 he also became a Group Leader in the Dementia Research Institute at UCL.
Paul’s scientific contributions span from ion channel neurobiology, the biology of schizophrenia, pluripotent stem cell-based disease modelling through to neurodegenerative diseases. He has lead drug and cell therapy programmes from basic research through to clinical trials and has co-authored around 200 scientific publications. He served on a range of advisory boards/committees including the MRC Neuroscience and Mental Health Board, the MRC Regenerative Medicine Research Committee and MRC UK Regenerative Medicine Platform Board, the Biological Sciences committee for assessment of UK University & Research Institutions (RAE 2008) and the Neuroscience, Psychiatry and Psychology committee for assessment of UK University & Research Institutions (REF 2014).
Head of Chemistry
Paul received his PhD in organic chemistry at the University of Nottingham, before pursuing postdoctoral research at Harvard University and Stanford University. Paul started his career in drug discovery in 1994 as a medicinal chemist with Pfizer at Sandwich (UK), before moving into the position of Research Project Leader, with responsibility for delivering projects from the exploratory portfolio through to clinical first in human studies. In 2009, Paul joined Pfizer’s Regenerative Medicine and Epigenetic unit where he led the exploratory chemistry team in support of the unit’s small molecule and stem cell therapies for the treatment of neuroregeneration with an emphasis on a chemogenomic approach towards phenotypical screening to identify new drug targets for dementia. In addition, he led Pfizer’s open access collaboration with the Structural Genomics Consortium to identify new chemical probes for epigenetic research.
In 2012 he was appointed as Professor and Chair of Medicinal Chemistry at the UCL School of Pharmacy where his research activities were focussed on the identification of new small molecule chemical probes for epigenetic drug targets. In January 2016, Paul moved to the UCL Faculty of Brain Sciences to become the Head of Chemistry for the Alzheimer’s Research UK UCL Drug Discovery Institute.
Paul has co-authored over 100 scientific publications including 21 patents and has served on the scientific advisory boards for ‘not-for-profit’ organisations such as Medicines for Malaria Venture (MMV) and Salvensis (rare and neglected diseases).
In conjunction with the CSO and Head of Chemistry, our Leadeship Team manages the drug discovery operations of the institute.
Sarah is an experienced neurobiologist working on drug discovery projects ranging from target identification and validation to lead optimisation. Her work at the DDI has been focused on synaptic and neurovascular health as well as neuroinflammation, and she leads a platform exploring the potential of astrocytes as new therapeutic targets in Alzheimer’s disease. Prior to joining the DDI, Sarah completed her PhD in Paris and her first post-doctoral training post at UCL. During this time, she worked on neuro-glia cross-talk in physiological or pathological conditions.
Lorenza obtained a first-class honours degree in Biotechnology applied to Pharmacy from the University of Milan, Italy. She then received a PhD in Medical Neurosciences at Charité University in Berlin, Germany. Lorenza joined the Neurodegeneration Biology group within the DDI in 2017 where she developed microglia model systems to characterise and validate potential drug targets for dementia and neurodegenerative diseases. Lorenza now leads a multidisciplinary team of scientists that has responsibility for the Neuroinflammation programme, and additionally participates in the screening and pharmacology activities of the DDI.
Emma obtained her BSc hons degree in Neuroscience from The University of Sheffield. She has over 20 years drug discovery experience in neuroscience gained within the pharmaceutical companies MSD and Pfizer, working primarily on GPCR based targets, but also on transporters, stem cells and biochemical targets. She has extensive experience in developing and delivering cell-based functional assays for high throughput screens as well as in classical pharmacology. Emma joined the UCL DDI in April 2016.
Fredrik is a Senior Research Associate at the Alzheimer’s Research UK UCL Drug Discovery Institute. He was awarded his Ph.D. from Uppsala University, Sweden, after which he obtained a postdoctoral fellowship from the Swedish Pharmaceutical Society for research in cheminformatics at the University of Cambridge with Dr Andreas Bender. He has is an expert on structure-based drug discovery and computational methods for drug discovery.
Lead Academic Scientists
Our Lead Academic Scientists act as ambassadors for the UCL Drug Discovery Institute, facilitating interactions with scientists and access to resources within UCL and beyond.
Prof Schiavo gained his degree in Chemistry and Pharmaceutical Technology and a PhD in Biological Sciences from the University of Padua, Italy, and received postdoctoral training at the University of Padua and at the Memorial Sloan Kettering Cancer Center in New York, USA. He was then recruited as junior group leader at the Cancer Research UK London Research Institute, where he has been Head of the Molecular NeuroPathobiology Laboratory until 2013. In 2014, he moved to University College London as Professor of Cellular Neurobiology at the Institute of Neurology. During his career, Prof Schiavo performed functional analyses on the mechanism of action of several bacterial toxins, such as diphtheria and pertussis toxins, and tetanus and botulinum neurotoxins. These studies provided a step-change in the molecular understanding of the machinery controlling neurotransmitter release and contributed to the first recombinant diphtheria vaccine now used worldwide in humans. The current goal of Professor Schiavo’s research is to understand the mechanisms underlying neuronal membrane trafficking, in particular axonal transport, and how neurons control the uptake and sorting of ligands in health and disease.
Prof Hardy is a geneticist and molecular biologist whose research interests focus on neurological disease. He received his B.Sc. (Hons) degree from the University of Leeds and his Ph.D. from Imperial College London, where he studied dopamine and amino acid neuropharmacology. Prof Hardy received his postdoctoral training at the MRC Neuropathogenesis Unit in Newcastle upon Tyne, and then further postdoctoral work at the Swedish Brain Bank in Umeå, Sweden where he started to work on Alzheimer’s disease. He became Assistant Professor of Biochemistry at St. Mary’s Hospital, Imperial College, in 1985 and initiated genetic studies of Alzheimer’s disease whilst there. He was appointed Associate Professor in 1989 and then took the Pfeiffer Endowed Chair of Alzheimer’s Research at the University of South Florida, in Tampa in 1992.
In 1996 he moved to the Mayo Clinic in Jacksonville, Florida, as Consultant and Professor of Neuroscience. He became Chair of Neuroscience in 2000 and moved to NIA as Chief of the Laboratory of Neurogenetics in 2001. He won the MetLife, the Allied Signal and the Potamkin Prize for his work in describing the first genetic mutations, in the amyloid gene in Alzheimer’s disease, in 1991. He was Head of the Neurogenetics Section, National Institute of Ageing, Bethesda, USA and in 2007 took up the Chair of Molecular Biology of Neurological Disease at the UCL Institute of Neurology. With over 23,000 citations, Prof Hardy is the most cited Alzheimer’s disease researcher in the UK (5th internationally). In recognition of his exceptional contributions to science, he was elected a Fellow of the Royal Society in 2009. John won the Breakthrough Prize 2015 for his tremendous work on Alzheimer’s disease.